Eltrombopag

證據等級: L5

預測適應症: 1 個

Eltrombopag: From Thrombocytopenia to HIV Infectious Disease

One-Sentence Summary

Eltrombopag is a thrombopoietin (TPO) receptor agonist whose clinical evidence base centers on thrombocytopenia associated with chronic liver disease and hepatitis C infection; it is not currently marketed in Finland. The TxGNN model predicts a possible link to HIV infectious disease, but on closer review the supporting evidence almost entirely concerns HIV-associated immune thrombocytopenia (ITP) or immune reconstitution thrombocytopenia rather than direct antiviral activity, with 5 clinical trials and 10 publications currently identified.

Quick Overview

Item	Content
Original Indication	Not documented in this dataset (no Finland market authorization on file); trial evidence indicates historical/investigational use for thrombocytopenia in chronic liver disease and hepatitis C
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.26%
Evidence Level	L4
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data (original_moa) is not available in the drug record itself. Based on the evidence pack's own repurposing analysis, eltrombopag is a TPO (thrombopoietin) receptor agonist that works by stimulating megakaryocyte production and raising platelet counts. This mechanism has no direct link to HIV viral replication or the infection process itself.

Almost all of the identified clinical trials and case reports actually describe eltrombopag being used to manage thrombocytopenia that occurs alongside HIV infection — either as HIV-associated ITP, immune reconstitution thrombocytopenia after starting HAART, or thrombocytopenia in the closely related setting of chronic HCV/liver disease. This is a supportive-care use pattern, not a demonstration of anti-HIV efficacy.

Only one source, an in vitro FDA-drug-library screen (PMID 32977702), raises a mechanistic hypothesis that eltrombopag might modulate HIV-1 proviral transcription — potentially relevant to "shock and kill" latency-reversal strategies — but this is preclinical and unvalidated in humans. The TxGNN label "HIV infectious disease" should therefore be interpreted cautiously: the real, evidence-backed repurposing signal is eltrombopag for HIV-associated thrombocytopenia/ITP, not treatment of HIV infection itself.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00678587	Phase 3	Terminated	292	Evaluated eltrombopag to reduce platelet transfusion needs in thrombocytopenic chronic liver disease patients undergoing invasive procedures; not HIV-specific
NCT00996216	Phase 3	Completed	27	Open-label rollover study of eltrombopag safety/efficacy in thrombocytopenic HCV patients eligible for antiviral therapy
NCT01636778	Phase 2	Completed	45	Assessed ability of eltrombopag (SB-497115-GR) to raise/maintain platelet counts in HCV patients with compensated cirrhosis
NCT00529568	Phase 3	Completed	759	Large pivotal RCT of eltrombopag for thrombocytopenia in HCV patients initiating peginterferon/ribavirin therapy
NCT00516321	Phase 3	Completed	687	Companion pivotal RCT (peginterferon alfa-2a arm) for eltrombopag in HCV-related thrombocytopenia

Note: None of the above trials enrolled HIV-infected patients specifically or tested antiviral efficacy against HIV; all target thrombocytopenia in HCV/liver disease populations.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22185370	2012	Cohort	Platelets	Danish real-world cohort of TPO receptor agonist use (including eltrombopag) in refractory ITP, including secondary/infection-associated cases
19932434	2009	Review	Hematology/Oncology Clinics of North America	Reviews HCV, HIV, and H. pylori as infectious causes of chronic ITP; treating the underlying infection often improves thrombocytopenia
19245929	2009	Review	Seminars in Hematology	Discusses therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias, including HIV
24816314	2014	Review	Internal Medicine Journal	Reviews TPO receptor agonist use in immune thrombocytopenia of less than 6 months' duration
25504472	2015	Case series	J Int Assoc Provid AIDS Care	TPO receptor agonists (eltrombopag, romiplostim) used as salvage therapy in refractory HIV-associated ITP after HAART optimization
22992580	2012	Case report	AIDS	Eltrombopag successfully used without splenectomy for refractory HIV-related immune reconstitution thrombocytopenia
25333665	2014	Case report	AIDS	First report of eltrombopag successfully treating aplastic anaemia associated with HIV infection; showed immunomodulatory effect (reduced Th1/Th17, increased Treg/Th ratio)
28043314	2016	Case report	J Coll Physicians Surg Pak	HBV infection (not HIV) causing megaloblastic anemia and severe thrombocytopenia; general infection–thrombocytopenia link
24128106	2013	Case report	Farmacia Hospitalaria	Two case reports of eltrombopag for thrombocytopenia in chronic hepatitis C patients
32977702	2020	In vitro screening	Viruses	FDA-approved drug library screen identifying modulators of HIV-1 proviral transcription; basis for a preclinical latency-reversal hypothesis

Finland Market Information

Eltrombopag currently has no marketing authorization on record in Finland (0 authorizations, market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug-interaction data were retrievable at this time — this is flagged as a Blocking data gap (DG001) for TFDA-equivalent labeling and must be resolved before any safety evaluation.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the supporting evidence base actually addresses HIV-associated thrombocytopenia/ITP rather than treatment of HIV infection itself, and the drug is not currently marketed in Finland with no verified safety/labeling data available — evidence level L4 (preclinical/mechanistic and case-level only) does not support proceeding.

To proceed, the following is needed:

TFDA/regulatory-equivalent package insert data (warnings, contraindications) — currently a Blocking gap (DG001)
Confirmed mechanism of action (MOA) from DrugBank or primary literature (DG002)
Reframing of the indication hypothesis toward "HIV-associated thrombocytopenia/ITP" rather than "HIV infectious disease," followed by re-scoring
A prospective study (even small/observational) specifically enrolling HIV-infected patients with thrombocytopenia to validate the case-report-level signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.